AbbVie (ABBV) Net Margin (2012 - 2026)
AbbVie (ABBV) reported Net Margin of 4.65% for Q1 2026, down 501.0% year-over-year from 1.16% in Q1 2025, and down 57.46% on a QoQ basis from 10.92% in Q4 2025.
AbbVie (ABBV) has 15 years of Net Margin data on file, last reported at 4.65% in Q1 2026.
- Quarterly Net Margin fell 501.0% year-over-year to 4.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.8% (down 153.0% YoY) and the FY2025 annual result came in at 6.92%, down 69.0% from the prior year.
- Net Margin declined to 4.65% in Q1 2026 per ABBV's latest filing, from 10.92% in the prior quarter.
- Across five years, Net Margin topped out at 33.19% in Q1 2022 and bottomed at 0.79% in Q1 2023.
- The 5-year median for Net Margin is 9.66% (2025), against an average of 10.52%.
- The widest annual swing landed in 2023, when Net Margin slumped 3398 bps; it then soared 1194 bps in 2024.
- Tracing ABBV's Net Margin over 5 years: stood at 16.35% in 2022, then tumbled by 65 bps to 5.76% in 2023, then sank by 103 bps to 0.15% in 2024, then surged by 7271 bps to 10.92% in 2025, then tumbled by 57 bps to 4.65% in 2026.
- Per Business Quant, the three latest ABBV Net Margin figures stand at 4.65% (Q1 2026), 10.92% (Q4 2025), and 1.19% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.65% |
| Dec 31, 2025 | 10.92% |
| Sep 30, 2025 | 1.19% |
| Jun 30, 2025 | 6.10% |
| Mar 31, 2025 | 9.66% |
| Dec 31, 2024 | -0.15% |
| Sep 30, 2024 | 10.82% |
| Jun 30, 2024 | 9.49% |
| Mar 31, 2024 | 11.15% |
| Dec 31, 2023 | 5.76% |
| Sep 30, 2023 | 12.79% |
| Jun 30, 2023 | 14.62% |
| Mar 31, 2023 | -0.79% |
| Dec 31, 2022 | 16.35% |
| Sep 30, 2022 | 26.68% |
| Jun 30, 2022 | 6.36% |
| Mar 31, 2022 | 33.19% |
| Dec 31, 2021 | 27.17% |
| Sep 30, 2021 | 22.17% |
| Jun 30, 2021 | 5.33% |
| Mar 31, 2021 | 27.15% |
| Dec 31, 2020 | 0.12% |
| Sep 30, 2020 | 17.78% |
| Jun 30, 2020 | -7.32% |
| Mar 31, 2020 | 34.92% |
| Dec 31, 2019 | 32.18% |
| Sep 30, 2019 | 22.22% |
| Jun 30, 2019 | 8.98% |
| Mar 31, 2019 | 31.37% |
| Dec 31, 2018 | -21.99% |
| Sep 30, 2018 | 33.35% |
| Jun 30, 2018 | 23.96% |
| Mar 31, 2018 | 35.08% |
| Dec 31, 2017 | 0.67% |
| Sep 30, 2017 | 23.32% |
| Jun 30, 2017 | 27.58% |
| Mar 31, 2017 | 26.17% |
| Dec 31, 2016 | 20.47% |
| Sep 30, 2016 | 24.84% |
| Jun 30, 2016 | 24.95% |
| Mar 31, 2016 | 22.73% |
| Dec 31, 2015 | 23.70% |
| Sep 30, 2015 | 20.84% |
| Jun 30, 2015 | 1,276.64% |
| Mar 31, 2015 | 20.28% |
| Dec 31, 2014 | -14.86% |
| Sep 30, 2014 | 10.08% |
| Jun 30, 2014 | 22.29% |
| Mar 31, 2014 | 21.48% |
| Dec 31, 2013 | 22.07% |
| Sep 30, 2013 | 20.70% |
| Jun 30, 2013 | 22.76% |
| Mar 31, 2013 | 22.36% |
| Dec 31, 2012 | 29.58% |
| Sep 30, 2012 | 35.16% |
| Jun 30, 2012 | 28.20% |
| Mar 31, 2012 | 21.16% |